Skip to content
Tipifarnib
Tipifarnib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against CHURC1-FNTB protein.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0492——14
Myelodysplastic syndromesD009190D46472——11
LeukemiaD007938C95622——9
Megakaryoblastic leukemia acuteD007947C94.2451——9
Monocytic leukemia acuteD007948451——9
Myelomonocytic leukemia acuteD015479C92.5451——9
Erythroblastic leukemia acuteD004915EFO_1001257C94.0451——9
Pancreatic neoplasmsD010190EFO_0003860C25131——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50310———10
GlioblastomaD005909EFO_000051544———6
Myeloid leukemiaD007951C9234———6
GliosarcomaD01831632———4
Myelomonocytic leukemia chronicD015477C93.133———4
Multiple myelomaD009101C90.032———3
Basophilic leukemia acuteD015471C94.822———3
Eosinophilic leukemia acuteD01547222———3
Non-hodgkin lymphomaD008228C85.9—3———3
MedulloblastomaD008527—3———3
Show 53 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C807————7
Blast crisisD0017521————1
Myeloproliferative disordersD009196D47.11————1
LymphomaD008223C85.91————1
Plasma cell neoplasmsD0542191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTIPIFARNIB
INNtipifarnib
Description
Tipifarnib is a quinolone that is 1-methylquinolin-2-one which carries a 3-chlorophenyl and an amino(4-chlorophenyl)(1-methyl-imidazol-5-yl)methyl groups at the 4 and 6 positions, respectively (the R-isomer). It has a role as an antineoplastic agent, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor and an apoptosis inducer. It is a quinolone, a member of monochlorobenzenes, a member of imidazoles and a primary amino compound.
Classification
Small molecule
Drug classfarnesyl transferase inhibitor
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C
Identifiers
PDB—
CAS-ID192185-72-1
RxCUI—
ChEMBL IDCHEMBL289228
ChEBI ID—
PubChem CID159324
DrugBankDB04960
UNII IDMAT637500A (ChemIDplus, GSRS)
Target
Agency Approved
CHURC1-FNTB
CHURC1-FNTB
Organism
Homo sapiens
Gene name
CHURC1-FNTB
Gene synonyms
NCBI Gene ID
100529261
Protein name
CHURC1-FNTB protein
Protein synonyms
CAAX farnesyltransferase subunit beta, Protein farnesyltransferase subunit beta, Ras proteins prenyltransferase subunit beta
Uniprot ID
P49356
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,903 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
66 adverse events reported
View more details